For cell therapy to become mainstream, important issues such as management of risk and quality control need to be addressed, argues Duncan Borthwick, Global Marketing Manager at cell therapy manufacturing firm Solentim.
https://www.labiotech.eu/interview/solentim-cell-therapy/?itm_source=Bibblio-module-desktop&itm_medium=recommended-content&itm_campaign=content-recirculation
trans-bio-tex.com 